Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesis. We previously mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma to chromosome 1q42.3-q43 (refs 4-6). Here we show, through a combination of mapping critical recombinants, identifying individuals with germline mutations and screening known and predicted transcripts, that this gene encodes fumarate hydratase, an enzyme of the tricarboxylic acid cycle. Leiomyomatosis-associated mutations are predicted to result in absent or truncated protein, or substitutions or deletions of highly conserved amino acids. Activity of fumarate hydratase is reduced in lymphoblastoid cells from individuals with leiomyomatosis. This enzyme acts as a tumor suppressor in familial leiomyomata, and its measured activity is very low or absent in tumors from individuals with leiomyomatosis. Mutations in FH also occur in the recessive condition fumarate hydratase deficiency, and some parents of people with this condition are susceptible to leiomyomata. Thus, heterozygous and homozygous or compound heterozygous mutants have very different clinical phenotypes. Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“germline mutations in FH cause hereditary leiomyomatosis and renal cell cancer (HLRCC) (7).”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [7]
In the citing paper
“Familial cancer syndromes caused by fumarate hydratase (FH) or succinate dehydrogenase (SDH) deletion suggest that these TCA enzymes can behave as classical tumor suppressors.”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Tomlinson et al., 2002
In the citing paper
“Similarly, germline mutations in the broadly expressed enzyme fumarate hydratase (FH) cause hereditary leiomyomatosis and renal cell carcinoma, a familial syndrome of uterine and cutaneous leiomyomas and kidney cancer, without susceptibility to more common tumors (11).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [11]
In the citing paper
“In 2001, mutation of fumarate hydratase leading to its inactivation was discovered in renal cell cancer129. Mutation of this enzyme leads to fumarate accumulation not only in skin cancer and uterine leiomyomas but also in breast, bladder, and Leydig cell tumors130.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [130]
In the citing paper
“Consistently, heterozygous germline mutations in genes encoding the TCA cycle enzymes involved in the breakdown of these metabolites—SDH and FH—have been shown to facilitate the pathogenesis of certain rare cancers (e.g., paragangliomas) and inherited cancer-predisposition syndromes (181, 182, 183).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [183]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 1×
“Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumo”
ResultAstuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087 · cited 1×
“Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumo”
ResultMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875
Inherited susceptibility to uterine leiomyomas and renal cell cancer
Launonen, V., Vierimaa, O., Kiuru, M., Isola, J., Roth, S., Pukkala, E., Sistonen, P., Herva, R., & Aaltonen, L. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633798 · Cited by 669
Fumarase C, the stable fumarase of Escherichia coli, is controlled by the soxRS regulon.
Liochev, S. I., & Fridovich, I. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.5892 · Cited by 239
The VHL tumour-suppressor gene paradigm
Kaelin, W. G., & Maher, E. R. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01558-3 · Cited by 213 · cited 1×
“, individuals with von Hippel–Lindau syndrome are predisposed to both phaeochromocytomas and renal carcinoma”
BackgroundKiuru, M., Launonen, V., Hietala, M., Aittomäki, K., Vierimaa, O., Salovaara, R., Arola, J., Pukkala, E., Sistonen, P., Herva, R., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61757-9 · Cited by 209
Bourgeron, T., Chretien, D., Poggi-Bach, J., Doonan, S., Rabier, D., Letouzé, P., Munnich, A., Rötig, A., Landrieu, P., & Rustin, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117261 · Cited by 160
Alam, N. A., Bevan, S., Churchman, M., Barclay, E., Barker, K., Jaeger, E. E. M., Nelson, H. M., Healy, E., Pembroke, A. C., Friedmann, P. S., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/320124 · Cited by 160
Familial predisposition to uterine leiomyomas
Vikhliaeva, E. M., Сагдуллаевна, Х. З., & Nd, F. (1995) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(95)02533-i · Cited by 152 · cited 1×
“gif" NDATA ITEM> ]> Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesi”
Background
Cited by
Items 501–600 of 1,000
Current and upcoming mitochondrial targets for cancer therapy
Kim, H. K., Noh, Y. H., Nilius, B., Ko, K. S., Rhee, B. D., Kim, N., & Han, J. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.006 · Cited by 55
Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers
Sourbier, C., Liao, P., Ricketts, C. J., Wei, D., Yang, Y., Baranes, S. M., Gibbs, B. K., Ohanjanian, L., Krane, L. S., Scroggins, B. T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24112 · Cited by 52
Perturbations in hypoxia detection: A shared link between hereditary and sporadic tumor formation?
Sharifi, N., & Farrar, W. L. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2005.11.003 · Cited by 52
“Germline mutations in fumarate hydratase (FH) have been described in a syndrome that causes papillary renal cell carcinoma, cutaneous leiomyomata and multiple fibroids [10].”
BackgroundFamilial multiple cutaneous and uterine leiomyomas associated with papillary renal cell cancer
Chan, I., Wong, T., Martı́nez-Mir, A., Christiano, A. M., & McGrath, J. A. (2005) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2004.01675.x · Cited by 52
Egan, G., Khan, D. H., Lee, J. B., Mirali, S., Zhang, L., & Schimmer, A. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1227 · Cited by 53
“Germline mutations in fumarate hydratase lead to increased cellular fumarate (38) and are associated with cutaneous leiomyomas, uterine leiomyomas, and papillary renal cell cancer (39), whereas somatic mutations are associated with progression of chronic myeloid leukemia (40).”
BackgroundFerroptosis: Mechanism and connections with cutaneous diseases
Liu, L., Lian, N., Shi, L., Hao, Z., & Chen, K. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1079548 · Cited by 56
“Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a syndrome of inherited cancers, including cutaneous leiomyomas (CLMs), uterine fibroids, and aggressive kidney tumors (Tomlinson et al., 2002).”
BackgroundUdager, A. M., Alva, A. S., Chen, Y., Siddiqui, J., Lagstein, A., Tickoo, S. K., Reuter, V. E., Chinnaiyan, A. M., & Mehra, R. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000127 · Cited by 52
Rabban, J. T., Chan, E., Mak, J. S., Zaloudek, C. J., & Garg, K. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001222 · Cited by 51
Chan, E., Rabban, J. T., Mak, J. S., Zaloudek, C. J., & Garg, K. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001293 · Cited by 53
Genetic epidemiology of cancer: From families to heritable genes
Hemminki, K., Rawal, R., Chen, B., & Bermejo, J. L. (2004) · International Journal of Cancer · doi:10.1002/ijc.20355 · Cited by 51
Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics
Pal, S., Sharma, A. K., Mathew, S. P., & Jaganathan, B. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.955476 · Cited by 56
“Some of these enzymes also function as tumor suppressors and their loss of function mutations can drive tumor progression as in the case of Isocitrate dehydrogenase (IDH) 1 and 2 (11), Fumarate hydratase (FH) (12), and succinate dehydrogenase (SDH) (13).”
BackgroundInfluentialMitochondrial redox adaptations enable alternative aspartate synthesis in SDH-deficient cells
Hart, M. L., Quon, E., Vigil, A.-L. B. G., Engström, I., Newsom, O. J., Davidsen, K., Hoellerbauer, P., Carlisle, S. M., & Sullivan, L. B. (2023) · eLife · doi:10.7554/elife.78654 · Cited by 54
Yan, B. C., Mackinnon, A. C., & Al‐Ahmadie, H. A. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.7.1026 · Cited by 58
Exploring the Allosteric Territory of Protein Function
Tee, W.-V., Tan, Z. W., Lee, K., Guarnera, E., & Berezovsky, I. N. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c00540 · Cited by 50
Metabolic Rewiring and the Characterization of Oncometabolites
Beyoğlu, D., & Idle, J. R. (2021) · Cancers · doi:10.3390/cancers13122900 · Cited by 57
“A similar situation was reported for dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer with various FH mutations [42].”
BackgroundDahia, P. L. M. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.023 · Cited by 56
Genetic Basis of Cancer of the Kidney
Sudarshan, S., & Linehan, W. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.008 · Cited by 56
Conventional renal cancer in a patient with fumarate hydratase mutation
Lehtonen, H. J., Blanco, I., Piulats, J. M., Herva, R., Launonen, V., & Aaltonen, L. A. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.10.011 · Cited by 50
“families [1,2].”
BackgroundReprogramming of Metabolism in Kidney Cancer
Wettersten, H. I. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.12.002 · Cited by 53
Functional implications of fumarate-induced cysteine succination
Guberović, I., & Frezza, C. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.05.003 · Cited by 52
Nagy, A., Zoubakov, D., Stupar, Z., & Kovács, G. (2004) · International Journal of Cancer · doi:10.1002/ijc.11694 · Cited by 49
MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas
Kämpjärvi, K., Mäkinen, N., Mehine, M. M., Välipakka, S., Uimari, O., Pitkänen, E., Heinonen, H.-R., Heikkinen, T., Tolvanen, J., Ahtikoski, A. M., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.130 · Cited by 50
“HLRCC is a tumour predisposition syndrome caused by heterozygous germ-line mutations in fumarate hydratase (FH; Launonen et al, 2001; Tomlinson et al, 2002).”
BackgroundThe potential of breath analysis to improve outcome for patients with lung cancer
Antoniou, S., Gaude, E., Ruparel, M., van der Schee, M. P., Janes, S. M., & Rintoul, R. C. (2019) · Journal of Breath Research · doi:10.1088/1752-7163/ab0bee · Cited by 51
Zhao, J., Yart, A., Frigerio, S., Perren, A. A., Schraml, P., Weisstanner, C., Stallmach, T., Krek, W., & Moch, H. (2006) · Oncogene · doi:10.1038/sj.onc.1210131 · Cited by 49
“The MET, FH and BHD genes have been identified to cause HPRC syndrome, HLRCC syndrome and BHD syndrome, respectively (Schmidt et al., 1997; Nickerson et al., 2002; Tomlinson et al., 2002) and their somatic mutations were also found in some sporadic counterparts of their hereditary tumor subtypes (Schmidt et al.”
BackgroundInfluentialDNA methylation in human diseases
Younesian, S., Mohammadi, M. H., Younesian, O., Momeny, M., Ghaffari, S. H., & Bashash, D. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32366 · Cited by 54
The genetic basis of female reproductive disorders: Etiology and clinical testing
Layman, L. C. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.02.016 · Cited by 52
“disorder caused by mutations in the fumarate hydratase (FH gene) (Tomlinson et al., 2002).”
BackgroundRespiratory chain complex I is a mitochondrial tumor suppressor of oncocytic tumors
Kofler, B. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e247 · Cited by 49
“Subsequently, germline mutations in the fumarate hydratase (FH) gene and reduced fumarate hydratase activity were shown to predispose to hereditary leiomyomatosis, renal cancer, and Leydig cell tumors (4) (5).”
BackgroundRenal cell carcinoma in young FH mutation carriers: case series and review of the literature
Hol, J. A., Jongmans, M. C. J., Littooij, A. S., de Krijger, R. R., Kuiper, R. P., van Harssel, J. J. T., Mensenkamp, A. R., Simons, M., Tytgat, G. A. M., van den Heuvel‐Eibrink, M. M., et al. (2019) · Familial Cancer · doi:10.1007/s10689-019-00155-3 · Cited by 48
Rescue of TCA Cycle Dysfunction for Cancer Therapy
Marquez, J. C., Flores, J., Kim, A. H., Nyamaa, B., Nguyen, A. T. T., Park, N., & Han, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122161 · Cited by 50
“%) of families were found to have clinically suggestive HLRCC with predisposed early onset, aggressive form of type 2 papillary renal cell carcinoma [87,88].”
BackgroundResponse to systemic therapy in fumarate hydratase–deficient renal cell carcinoma
Carril-Ajuria, L., Colomba, É., Cerbone, L., Romero, C., Crouzet, L., Laguerre, B., Thibault, C., Vicier, C., de Velasco, G., Fléchon, A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.009 · Cited by 47
Mitochondrial hyperfusion via metabolic sensing of regulatory amino acids
Abdullah, M. O., Zeng, R. X., Margerum, C. L., Papadopoli, D. J., Monnin, C., Punter, K. B., Chu, C., Al-Rofaidi, M., Al‐Tannak, N. F., Berardi, D., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111198 · Cited by 49
“Therefore, we investigated UOK262 Fh ( / ) HLRCC tumor-derived cells (Yang et al., 2010).”
BackgroundHereditary and familial kidney cancer
Coleman, J., & Russo, P. (2009) · Current Opinion in Urology · doi:10.1097/mou.0b013e32832f0d40 · Cited by 48
Multifaceted Roles of the KEAP1–NRF2 System in Cancer and Inflammatory Disease Milieu
Panda, H., Wen, H., Suzuki, M., & Yamamoto, M. P. (2022) · Antioxidants · doi:10.3390/antiox11030538 · Cited by 47
“The third pathway entails cysteine modification in KEAP1 through oncometabolites, such as fumarate, causing persistent NRF2 activation similar to that observed in smooth cell tumors [73].”
BackgroundRustin, P., & Kroemer, G. (2008) · Ernst Schering Research Foundation workshop/Ernst Schering Foundation Symposium proceedings · doi:10.1007/2789_2008_086 · Cited by 47
The genetic basis of renal cell carcinoma
Pavlovich, C. P., Schmidt, L. S., & Phillips, J. L. (2003) · Urologic Clinics of North America · doi:10.1016/s0094-0143(03)00023-5 · Cited by 55
“In addition, the PRCC seemed to be distinct histologically from the PRCC associated with HPRC [8,104].”
BackgroundRenal cancer: signaling pathways and advances in targeted therapies
Jiang, A., Li, J., He, Z., Liu, Y., Qiao, K., Fang, Y., Qu, L., Luo, P., Lin, A., & Wang, L. (2024) · MedComm · doi:10.1002/mco2.676 · Cited by 51
“33 chRCC is a rare subtype of RCC; however, its genetic alterations in the PI3K / AKT signaling pathway are highly significant, with approximately 32% of patients exhibiting mutations or deletions of pathway-related components.”
BackgroundLlamas‐Velasco, M., Requena, L., Kutzner, H., Schärer, L., Rütten, A., Hantschke, M., Paredes, B. E., & Mentzel, T. (2014) · Journal of Cutaneous Pathology · doi:10.1111/cup.12396 · Cited by 45
Leiomyoma Cutis: A Focused Review on Presentation, Management, and Association with Malignancy
Malik, K., Patel, P. S., Chen, J., & Khachemoune, A. (2015) · American Journal of Clinical Dermatology · doi:10.1007/s40257-015-0112-1 · Cited by 50
“Furthermore, although whole gene or exonic deletions/amplifications are not typically associated with HLRCC, abnormalities can occur at any point along the entire FH gene-coding region [54, 76, 77].”
BackgroundMolecular markers of paragangliomas/pheochromocytomas
Zhikrivetskaya, S. O., Snezhkina, A. V., Zaretsky, A. R., Alekseev, B. Y., Pokrovsky, A. V., Golovyuk, A. L., Melnikova, N. V., Stepanov, O. A., Kalinin, D. V., Moskalev, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15201 · Cited by 45
“Mutations in FH are associated with hereditary leiomyomatosis and renal cancer [105]; additionally, mutations were also found in some pheochromocytomas that resembled SDH-mutant tumors in their transcription and methylation profiles [98].”
BackgroundCancer: Untethering Mitochondria from the Endoplasmic Reticulum?
Herrera-Cruz, M. S., & Simmen, T. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00105 · Cited by 47
“Specifically, mutations in mtDNA can indirectly affect enzymes of the Krebs cycle, including fumarate hydratase (30), and isocitrate dehydrogenase (31).”
BackgroundTarhonskaya, H., Nowak, R. P., Johansson, C., Szykowska, A., Tumber, A., Hancock, R. L., Lang, P. A., Flashman, E., Oppermann, U. C. T., Schofield, C. J., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.08.007 · Cited by 47
“Elevated succinate and fumarate levels occur in paragangliomas, pheochromocytomas, in gastric tumours (succinate) and in heriaditary leiomyomatosis (fumarate) [33, 34].”
BackgroundŽdralević, M., Marchiq, I., de Padua, M. M. C., Parks, S. K., & Pouysségur, J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00313 · Cited by 52
“Interestingly, it was shown only later that loss-of-function mutations of the TCA cycle enzymes succinate dehydrogenase (10) and fumarate hydratase (11) were implicated in pathogenesis of several hereditary forms of cancer.”
BackgroundRole of coenzymes in cancer metabolism
Thapa, M., & Dallmann, G. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.027 · Cited by 49
Zhang, L., Walsh, M. F., Jairam, S., Mandelker, D. L., Zhong, Y., Kemel, Y. M., Chen, Y., Musheyev, D., Zehir, A., Jayakumaran, G., et al. (2019) · Human Mutation · doi:10.1002/humu.23900 · Cited by 45
Shuch, B. M., Li, S., Risch, H. A., Bindra, R. S., McGillivray, P. D., & Gerstein, M. (2020) · Cancer · doi:10.1002/cncr.32914 · Cited by 50
Cancer morphogenesis: role of mitochondrial failure.
Fosslien, E. (2008) · PubMed · Cited by 51
Human Fumarate Hydratase Is Dual Localized by an Alternative Transcription Initiation Mechanism
Dik, E., Naamati, A., Asraf, H., Lehming, N., & Pines, O. (2016) · Traffic · doi:10.1111/tra.12397 · Cited by 44
“A bi-allelic inactivation of FH has been detected in almost all HLRCC tumors, and therefore FH was suggested to function as a tumor suppressor (8,9).”
BackgroundJoberty, G., Böesche, M., Brown, J. A., Eberhard, D., Garton, N. S., Humphreys, P. G., Mathieson, T., Muelbaier, M., Ramsden, N. G., Reader, V., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00080 · Cited by 45
Analyzing Tumor Metabolism In Vivo
Faubert, B., & DeBerardinis, R. J. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121954 · Cited by 43
“…succinate dehydrogenase and fumarate hydratase function genetically as tumor suppressors, as mutations in these enzymes are responsible for familial cancer syndromes and some sporadically acquired cancers (Baysal et al. 2000, Castro-Vega et al. 2014, Ricketts et al. 2008, Tomlinson et al. 2002).”
BackgroundCarter, C. S., Skala, S. L., Chinnaiyan, A. M., McHugh, J. B., Siddiqui, J., Cao, X., Dhanasekaran, S. M., Fullen, D. R., Lagstein, A., Chan, M. P., et al. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000840 · Cited by 44
Next generation immunohistochemistry: Emerging substitutes to genetic testing?
Andrici, J., Gill, A. J., & Hornick, J. L. (2017) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2017.05.004 · Cited by 45
“Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) is an autosomal dominant disorder characterized by inherited predisposition to uterine and cutaneous leiomyomas and renal cell carcinoma (RCC).(53,54) The association between uterine and cutaneous leiomyomas was first described in 1973(55) and has been e…”
BackgroundWei, J., Chiriboga, L. A., Mizuguchi, M., Yee, H. T., & Mittal, K. (2004) · Modern Pathology · doi:10.1038/modpathol.3800283 · Cited by 44
100 years of the Warburg effect: a historical perspective
Hardie, D. G. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0173 · Cited by 48
“With a few notable exceptions discovered later (Baysal et al. 2000, Tomlinson et al. 2002, Gottlieb & Tomlinson 2005, Parsons et al. 2008), the majority of proto-oncogenes and tumour suppressors were proteins involved in cell signalling and cellular growth control, rather than metabolism.”
BackgroundRaman micro-spectroscopy reveals the spatial distribution of fumarate in cells and tissues
Kamp, M., Surmacki, J. M., Segarra‐Mondejar, M., Young, T. J., Chrabąszcz, K., Joud, F., Zecchini, V. R., Speed, A., Frezza, C., & Bohndiek, S. E. (2024) · Nature Communications · doi:10.1038/s41467-024-49403-w · Cited by 49
Identification of novel hereditary cancer genes by whole exome sequencing
Соколенко, А. П., Suspitsin, E. N., Kuligina, E. S., Валерьевич, Б. И., Frishman, D., & Имянитов, Е. Н. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.09.014 · Cited by 48
MacLennan, G. T., & Liang Cheng, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-23380-2_35 · Cited by 44
Global metabolomic profiling of uterine leiomyomas
Heinonen, H.-R., Mehine, M. M., Mäkinen, N., Pasanen, A. M., Pitkänen, E., Karhu, A., Sarvilinna, N. S., Sjöberg, J., Heikinheimo, O., Bützow, R. C., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.361 · Cited by 43
“…mutations in the tricarboxylic acid (TCA) cycle enzyme fumarate hydratase (FH) cause hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome, characterised by predisposition to type 2 papillary renal cell carcinoma, as well as uterine and cutaneous leiomyomas (Tomlinson et al, 2002).”
BackgroundMetabolism and Transcription in Cancer: Merging Two Classic Tales
Martín-Martín, N., Carracedo, A., & Torrano, V. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00119 · Cited by 49
“Inactivating mutations affecting the mitochondrial succinate dehydrogenase (SDH) complex subunits and fumarate hydratase (FH) are driver mutations in a subset of cancers (Tomlinson et al., 2002; Janeway et al., 2011; Pantaleo et al., 2011; Castro-Vega et al., 2014; Clark et al., 2014).”
BackgroundThe Genetic Heterogeneity of Uterine Leiomyomata
Lobel, M. K., Somasundaram, P., & Morton, C. C. (2006) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2005.12.006 · Cited by 47
Clinical and biochemical heterogeneity associated with fumarase deficiency
Ottolenghi, C., Hubert, L., Allanore, Y., Brassier, A., Altuzarra, C., Mellot‐Draznieks, C., Bekri, S., Goldenberg, A., Veyrieres, S., Boddaert, N., et al. (2011) · Human Mutation · doi:10.1002/humu.21534 · Cited by 46
“Although at the present time, most mutations known to be involved in cancer are different from those involved in the metabolic disease [Bayley et al., 2008], exceptions have already been reported [Tomlinson et al., 2002].”
BackgroundHan, S. S., Yeager, M., Moore, L. E., Wei, M.-H., Pfeiffer, R. M., Touré, O., Purdue, M. P., Johansson, M., Scélo, G., Chung, C. C., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr551 · Cited by 44
Bhola, P. T., Gilpin, C., Smith, A., & Graham, G. E. (2018) · Familial Cancer · doi:10.1007/s10689-018-0076-4 · Cited by 45
“HLRCC is caused by autosomal dominant germline mutations in the fumarate hydratase (FH) gene [1].”
BackgroundThe genetic basis of cancer of kidney cancer: implications for gene‐specific clinical management
Linehan, W. M., Grubb, R. L., Coleman, J., Zbar, B., & Walther, M. M. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05189.x · Cited by 43
Origin of Uterine Fibroids: Conversion of Myometrial Stem Cells to Tumor-Initiating Cells
Elkafas, H., Qiwei, Y., & Al-Hendy, A. A. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1607205 · Cited by 42
DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma
Slater, A., Alokail, M. S., Gentle, D., Yao, M., Kovács, G., Maher, E. R., & Latif, F. (2013) · Epigenetics · doi:10.4161/epi.23817 · Cited by 44
Human Metabolic Enzymes Deficiency: A Genetic Mutation Based Approach
Chaturvedi, S., Singh, A. K., Keshari, A. K., Maity, S., Sarkar, S., & Saha, S. (2016) · Scientifica · doi:10.1155/2016/9828672 · Cited by 43
Targeting fuel pocket of cancer cell metabolism: A focus on glutaminolysis
Sharma, S., Agnihotri, N., & Kumar, S. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114943 · Cited by 45
Linehan, W. M., Srinivasan, R., & Garcia, J. A. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.05.009 · Cited by 42
Teng, L. L., Chen, Y., Cao, Y. W., Wang, W., Xu, Y., Wang, Y., Jia-yin, L., Li, C., & Su, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.8211 · Cited by 56
“…and providing early diagnosis of RCC. High ACLY expression in RCC might be involved in the metabolic shift of this cancer, suggesting that RCC progress relies on aerobic glycolysis, which is also observed in fumarate hydratase (FH)-deficient RCC and succinate dehydrogenase-deficient RCC (18,19).”
Role of Hormones in Common Benign Uterine Lesions: Endometrial Polyps, Leiomyomas, and Adenomyosis
Kossaï, M., & Penault-Llorca, F. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38474-6_3 · Cited by 47
Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors
Patra, S., Elahi, N., Armorer, A., Arunachalam, S., Omala, J., Hamid, I., Ashton, A. W., Joyce, D. A., Jiao, X., & Pestell, R. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700629 · Cited by 44
Johnson, T. I., Costa, A. S. H., Ferguson, A. N., & Frezza, C. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0912-3 · Cited by 40
Exomic landscape of MED12 mutation‐negative and ‐positive uterine leiomyomas
Mäkinen, N., Vahteristo, P., Bützow, R. C., Sjöberg, J., & Aaltonen, L. A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28410 · Cited by 40
“The syndrome is caused by heterozygous germline mutations in fumarate hydratase (FH), which encodes an enzyme fumarase of tricarboxylic acid cycle.(6) We have studied uterine leiomyomas by exome sequencing and identified mediator complex subunit 12 (MED12) mutations in 70% of the tumors.”
BackgroundBiomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer
Yuasa, T., Takahashi, S., Hatake, K., Yonese, J., & Fukui, I. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02054.x · Cited by 41
Tracing Renal Cell Carcinomas back to the Nephron
Lindgren, D., Sjölund, J., & Axelson, H. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.003 · Cited by 46
Zhang, X., Dong, W., Zhang, J., Liu, W., Yin, J., Shi, D., & Ma, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.740487 · Cited by 49
An iron regulatory-like protein expressed in Plasmodium falciparum displays aconitase activity
Hodges, M. G., Yikilmaz, E., Patterson, G. H., Kasvosve, I., Rouault, T. A., Gordeuk, V. R., & Loyevsky, M. (2005) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2005.05.004 · Cited by 41
Familial Renal Cancer: Molecular Genetics and Surgical Management
Barrisford, G. W., Singer, E. A., Rosner, I. L., Linehan, W. M., & Bratslavsky, G. (2011) · International Journal of Surgical Oncology · doi:10.1155/2011/658767 · Cited by 40
Metabolic Plasticity and Epithelial-Mesenchymal Transition
Thomson, T. M., Balcells, C., & Cascante, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070967 · Cited by 42
Mitochondrial biology in airway pathogenesis and the role of NRF2
Cho, H., & Kleeberger, S. R. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01182-5 · Cited by 44
Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome
Davies, H. R., Hodgson, K., Schwalbe, E. C., Coxhead, J., Sinclair, N., Zou, X., Cockell, S., Husain, A., Nik‐Zainal, S., & Rajan, N. (2019) · Nature Communications · doi:10.1038/s41467-019-12746-w · Cited by 44
Metabolic Drivers in Hereditary Cancer Syndromes
Sciacovelli, M., Schmidt, C., Maher, E. R., & Frezza, C. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033612 · Cited by 48
Zheng, L., Zhu, Z.-R., Sneh, T., Zhang, W.-T., Wang, Z.-Y., Wu, G., He, W., Qi, H., Wang, H., Wu, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165028 · Cited by 43
Familial Leiomyomatosis: A Review and Discussion of Pathogenesis
Garman, M., Blumberg, M., Ernst, R., & Raimer, S. (2003) · Dermatology · doi:10.1159/000071802 · Cited by 39
Role of Mitochondrial Mutations in Cancer
Baysal, B. E. (2006) · Endocrine Pathology · doi:10.1385/ep:17:3:203 · Cited by 41
“hereditary leiomyomatosis renal cancer (HLRCC) [ 11 ].”
BackgroundRenal Cell Carcinoma: Recent Advances in Genetics and Imaging
Choudhary, S., Sudarshan, S., Choyke, P. L., & Prasad, S. R. (2009) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2009.03.003 · Cited by 39
TCA cycle-derived oncometabolites in cancer and the immune microenvironment
Sarkar, S., Chang, C.-I., Jean, J., & Wu, M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01186-y · Cited by 45
“This inhibition leads to stabilization of hypoxia-inducible factors (HIFs), altered epigenetic landscapes, and inflammatory signaling pathways [16–19].”
Renal cell carcinoma: translational aspects of metabolism and therapeutic consequences
Yang, O. C. Y., Maxwell, P. H., & Pollard, P. J. (2013) · Kidney International · doi:10.1038/ki.2013.245 · Cited by 41
Cheng, L., Williamson, S. R., Zhang, S., MacLennan, G. T., Montironi, R., & López-Beltrán, A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.72 · Cited by 38
Inherited kidney cancer syndromes
Ball, M. W., & Shuch, B. M. (2019) · Current Opinion in Urology · doi:10.1097/mou.0000000000000646 · Cited by 38
Regulation of tumor metabolism by post translational modifications on metabolic enzymes
Dessai, A. S., Kalhotra, P., Novickis, A. T., & Dasgupta, S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00521-x · Cited by 42
“Loss of function germline mutation of FH is associated with renal cell cancer and hereditary leiomyomatosis [119].”
BackgroundOoi, A., & Furge, K. A. (2012) · 癌症:英文版 · doi:10.5732/cjc.012.10102 · Cited by 41
Respiratory chain defects: what do we know for sure about their consequences in vivo?
Brière, J.-J., Chrétien, D., Bénit, P., & Rustin, P. (2004) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2004.07.002 · Cited by 38
Abu‐Amero, K. K., Alzahrani, A. S., Zou, M., & Shi, Y. (2005) · Oncogene · doi:10.1038/sj.onc.1209094 · Cited by 38
van Spaendonck‐Zwarts, K. Y., Badeloe, S., Oosting, S. F., Hovenga, S., Semmelink, H. J. F., van Moorselaar, R. J. A., van Waesberghe, J. H., Mensenkamp, A. R., & Menko, F. H. (2011) · Familial Cancer · doi:10.1007/s10689-011-9491-5 · Cited by 37
Tissue-Specific Stem Cells in the Myometrium and Tumor-Initiating Cells in Leiomyoma1
Ono, M., Bulun, S. E., & Maruyama, T. (2014) · Biology of Reproduction · doi:10.1095/biolreprod.114.123794 · Cited by 46
“At the genetic level, several mutations, such as germline mutations causing fumarate hydratase deficiency, have been associated with leiomyoma formation [43].”
BackgroundTargeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context
Bi, J., Wu, S., Zhang, W., & Mischel, P. S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.05.002 · Cited by 37
Structural, biochemical and biophysical characterization of recombinant human fumarate hydratase
Aleixo, M. A. A., Rangel, V. L., Rustiguel, J. K. R., Padua, R. A. P., & Nonato, M. C. (2019) · FEBS Journal · doi:10.1111/febs.14782 · Cited by 37
Molecular and biochemical investigations in fumarase deficiency
Deschauer, M., Gizatullina, Z. Z., Schulze, A., Pritsch, M., Knöppel, C., Knape, M., Zierz, S., & Gellerich, F. N. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.01.007 · Cited by 37
Understanding the natural biology of kidney cancer: implications for targeted cancer therapy.
Klatte, T., Pantuck, A. J., Kleid, M. D., & Belldegrun, A. S. (2007) · Europe PMC (PubMed Central) · Cited by 37
Metadata
- Authors
- The Multiple Leiomyoma Consortium
- Venue
- Nature Genetics
- Published
- 2002-02-25
- Volume
- 30
- Issue
- 4
- Pages
- 406-410
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1967291345
- Cited by
- 1,635
- References
- 17
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 64 · 2023: 57 · 2022: 65 · 2021: 80 · 2020: 93 · 2019: 86 · 2018: 81 · 2017: 90 · 2016: 106 · 2015: 89 · 2014: 85 · 2013: 82 · 2012: 82
- FWCI
- 56.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- U.S. Public Health Service (U59309)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Uterine Myomas and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- fumarate hydratase, FH gene, germline mutations, uterine fibroids, cutaneous leiomyoma, papillary renal cell carcinoma, cancer susceptibility, tumor suppressor, fumarate hydratase deficiency, compound heterozygosity, TCA cycle, fibroid pathogenesis
- MeSH terms
- Alleles, Carcinoma, Papillary, Carcinoma, Renal Cell, Chromosomes, Human, Pair 1, Exons, Female, Fumarate Hydratase, Genes, Dominant, Genetic Markers, Humans, Kidney Neoplasms, Leiomyoma, Male, Mutation, Pedigree, Recombination, Genetic, Uterine Neoplasms, Gene Deletion, In Situ Hybridization, Fluorescence, Sequence Analysis, DNA, Germ-Line Mutation, Leiomyoma, Epithelioid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.